Ontology highlight
ABSTRACT:
SUBMITTER: Raffi F
PROVIDER: S-EPMC5427981 | biostudies-literature | 2017 Jun
REPOSITORIES: biostudies-literature
Raffi François F Orkin Chloe C Clarke Amanda A Slama Laurence L Gallant Joel J Daar Eric E Henry Keith K Santana-Bagur Jorge J Stein David K DK Bellos Nicholaos N Scarsella Anthony A Yan Mingjin M Abram Michael E ME Cheng Andrew A Rhee Martin S MS
Journal of acquired immune deficiency syndromes (1999) 20170601 2
In a double-blind, phase 3 trial, 663 HIV-infected, virologically suppressed adults were randomized to switch to tenofovir alafenamide (TAF; n = 333) vs. remain on tenofovir disoproxil fumarate (TDF; n = 330), each coformulated with emtricitabine (FTC), while continuing their third agent (boosted protease inhibitor or unboosted third agent). At week 96, 88.6% on FTC/TAF and 89.1% on FTC/TDF had HIV-1 RNA <50 copies per milliliter [adjusted difference -0.5% (95% confidence interval: -5.3 to 4.4%) ...[more]